Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles
- PMID: 33899326
- PMCID: PMC8286350
- DOI: 10.1111/liv.14903
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles
Abstract
Background/aims: Allopurinol can cause HLA class I-associated life-threatening severe skin reactions. However, HLA risk and association with clinical features in allopurinol hepatotoxicity are unknown.
Methods: Eleven of 17 patients with suspected allopurinol hepatotoxicity enrolled into the Drug-Induced Liver Injury Network were adjudicated as definite, highly likely, or probable. High-resolution HLA sequencing was undertaken in cases and compared with population and other DILI controls.
Result: Median age was 60 years, 54% were male, and 63% African- American, 27% Caucasian, and 9% Hispanic. Patients presented at a median of 52 days after starting allopurinol, all were hospitalized and six were jaundiced. The median peak ALT, alkaline phosphatase, and total bilirubin were 525 U/L, 521 U/L, and 7.8 mg/dl, respectively, with a median R ratio of 2.7 at onset. During follow-up, nine patients were treated with corticosteroids including five of the six with suspected DRESS. Three patients died including two from liver failure at 38 and 45 days after onset, and the remaining eight recovered. Three HLA alleles were found to be overrepresented in allopurinol cases, particularly in African Americans: HLA-B*58:01, which has been previously linked to severe skin reactions, and HLA-B*53:01 and HLA-A*34:02, all of which are more frequently found in African Americans than European Americans or Latinos.
Conclusions: Allopurinol hepatotoxicity is associated with systemic hypersensitivity, a short latency to onset, African-American race and three HLA risk alleles, HLA-B*58:01, HLA-B*53:01, and HLA-A*34:02-58:01 testing may help confirm a diagnosis of hepatotoxicity in allopurinol-treated patients.
Keywords: genetic polymorphisms; gout; human leukocyte antigen; hyperuricaemia; liver injury.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Figures
References
-
- Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61 - PubMed
-
- Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterol 1986; 90: 188–90. - PubMed
-
- Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J 2000; 41: 156–60 - PubMed
-
- Kaniwa N, Saito Y, Aihara M, et al. ; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 RR025761/RR/NCRR NIH HHS/United States
- U24 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083020/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- U01 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083023/DK/NIDDK NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- U01 DK065211/DK/NIDDK NIH HHS/United States
- U01 HG007417/HG/NHGRI NIH HHS/United States
- U01 DK083027/DK/NIDDK NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK100928/DK/NIDDK NIH HHS/United States
- UL1 TR000083/TR/NCATS NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- U01 DK082992/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
